By Denny Jacob
Arvinas shares dived 40% following results from a Phase 3 clinical trial evaluating vepdegestrant as a treatment for a type of metastatic breast cancer.
Shares were trading around $10.35. The stock is down 61% over the last year.
The biopharmaceutical company in conjunction with Pfizer said the trial did not reach statistical significance in improvement in progression-free survival in the intent-to-treat population.
The trial, however, did meet its primary endpoint in the estrogen receptor 1-mutual population, which the company said demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant.
The two companies in July 2021 announced plans to collaborate on the co-development and co-commercialization of vepdegestrant.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 11, 2025 08:37 ET (12:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。